Kornimate/medical-research-clean huggingface dataset:
intravenous vs oral acetaminophen in postoperative hip fracture adult patients

Conditions: Hip-fracture; Surgery

Summary: the intact-hip trial study will evaluate feasibility of conducting a randomized, double-blinded controlled trial comparing postoperative treatment with intravenous (iv) acetaminophen versus oral acetaminophen, in older adults undergoing hip fracture surgery. the results of this feasibility trial will be used to inform designing a larger, multi-center, randomized controlled trial to assess the efficacy of iv acetaminophen compared to oral acetaminophen to reduce delirium and improve other clinical and patient-centered outcomes after hip fracture surgery. it will randomize 42 older adults to receive either oral or iv acetaminophen after hip fracture surgery.


Eligibility criteria:
inclusion criteria: * 60 years of age and older * patients who were ambulating without human assistance before fracture, with any type of non-neoplastic hip fracture * patients undergoing surgical treatment as an inpatient exclusion criteria: * patients with neoplastic hip fracture * severe cognitive impairment (montreal cognitive assessment (moca) \<10) * pre-existing delirium * known hypersensitivity or allergy to acetaminophen * severe or chronic liver or kidney dysfunction * planned postoperative ventilation * swallowing issues and/or dysphagia * english language limitation * weight \<50kg

Keywords: elderly acetaminophen oral vs intravenous hip fracture surgery
the cutting efficiency of hybrid tips in different grades of cataract

Conditions: Cataract

Summary: the objective is to assess the efficiency (as measured by phaco time, aspiration time, and fluid use) of the hybrid tip in removing cataract grade 3 \& 4 in high and low intraocular pressure (iop) settings.

this study is a single site, single-masked, randomized, prospective, observational study of the efficiency of the hybrid tip in removing cataract grade 3 \& 4 in high and low intraocular pressure (iop) settings. subjects will be assessed pre-operatively, operatively and at 1 day and 1 week post-operatively. clinical evaluations will include measurement of visual acuity, central corneal thickness, iop, visual analog pain scale, and slit lamp examination.

Eligibility criteria:
subjects are eligible for the study if they meet the following criteria: note: ocular criteria must be met in both eyes. * be eligible to undergo sequential bilateral uncomplicated cataract surgery * grade 3 or 4 cataract (pns or locs iii) * undergo uneventful cataract surgery * gender: males and females. * age: 50 or older. * willing and able to provide written informed consent for participation in the study. * willing and able to comply with scheduled visits and other study procedures. if any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study. * patient under 50 years of age * unable to complete sequential bilateral cataract surgery in both eyes by the same surgeon (js) * patient cataract surgery complicated by posterior capsular tear * any disease state deemed by pi that increases risk of complicated cataract surgery (ie pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma. ra, prior refractive surgery, etc) the principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial. pregnancy has a known effect on the stability of refractions and visual acuity. as such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
the noninvasive ventilation to covid-19 patients

Conditions: Noninvavie Ventilation to Patients With COVID-19

Summary: noninvasive ventilation(niv) is an important treatment to the respiratory failure patients.the severe corona virus disease-19(covid-19) patients are incline to respiratory failure.the niv may reduce the intubtion rate.this research was taken to investigate the factor to the success of the noninvasive ventilation to the covid-19 patients with respiratory failure.

noninvasive ventilation(niv) is an important treatment to the respiratory failure patients.the severe corona virus disease-19(covid-19) patients are incline to respiratory failure.the niv may reduce the intubtion rate.this research was taken to investigate the factor to the success of the noninvasive ventilation to the covid-19 patients with respiratory failure.we wish to raise the success rate to covid-19 patients with respiratory failure.more critically ill covid-19 patients could avoid the intubtion.

Eligibility criteria:
inclusion criteria: 1. shortness of breath, rr\>30 times per minute; 2. at room air, spo2 lower than 93%; 3. the partial pressure of arterial blood oxygen (pao2)/the fraction of inspired oxygen (fio2) ≤ 300mmhg; 4. ct（computed tomography） chest imaging shows that lung damage develops significantly within 24 to 48 hours. exclusion criteria: 1. severe cardiovascular disease, 2. respiratory arrest, 3. cardiovascular instability (hypotension, arrhythmias, myocardial infarction), 4. change in mental status or patients who were uncooperative, high risk of aspiration, viscous or copious 5. secretions, 6. recent facial or gastroesophageal surgery, 7. craniofacial trauma, 8)fixed nasopharyngeal abnormalities, 9）burns, 10) extreme obesity.

Keywords: noninvavie ventilation covid-19 respiratory failure
facilitation of corneal re-epithelialization after photorefractive keratectomy

Conditions: Corneal Erosion

Summary: photorefractive keratectomy (prk) or surface ablation is one of the most commonly used surgical procedures to correct refractive errors, which was proved to be safe and effective. in prk, the corneal epithelium is removed by various techniques such as diluted alcohol, manual debridement, brush, or excimer laser, before the refractive excimer laser ablation of the corneal stroma. compared to laser in situ keratomileusis (lasik), the two main drawbacks for prk are slower visual recovery and discomfort in the immediate postoperative period, due to the epithelial removal. corneal healing is a complex process involving cellular interaction and reaction with various molecules (proteases, growth factors, and epithelial and stromal cytokines). enhanced corneal re-epithelialization may reduce the risk for corneal infection and stromal scarring or melting. over the past few years, a new type of matrix therapy by regenerating agent (rgta) has provided encouraging results, accelerating the healing of chronic skin ulcers in diabetes or vascular origin. rgtas mimic the action of heparin sulfate molecules, breaking the negative repair-destruction cycle occurring in chronic lesions and inhibit proteolytic enzymes in vitro. in the domain of ophthalmology, rgta has been reported to show encouraging results in the treatment of corneal ulcer and dystrophies of various etiologies. the cacicol20 is an rgta that binds to matrix proteins to protect them from proteolysis; the extracellular matrix microenvironment protection improves the production of signals and growth factors needed for tissue healing. it is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate described and synthesized as in us patent number 6689741, with dextran t40 and 0.9% sodium chloride as excipients. it contains no component of animal or biological origin, and penetrates into the cornea without crossing descemet´s membrane (no intraocular penetration). the cacicol20 has been reported to be effective in treatment of neurotrophic ulcers and persistent epithelial defects which were unresponsive to the common treatment approaches. therefore, we expect that the cacicol20 may facilitate the corneal re-epithelialization after prk.


Eligibility criteria:
inclusion criteria: * patients undergoing bilateral prk surgeries for treatment of refractive error * age over 18 years * refractive stability for at least 2 years exclusion criteria: * ocular pathology, including keratoconus or suspected keratoconus, glaucoma, and epithelial defects * previous corneal surgery * systemic disease that might affect corneal wound healing.
prevention of dialysis catheter malfunction with prophylactic use of a taurolidine containing urokinase

Conditions: Patency; Infection

Summary: the objective of our study is to investigate whether the substitution of the standard locking solution with a locking solution containing taurolidine and urokinase weekly (taurolock ™ u 25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis patients with a history of tcc dysfunction requiring urokinase therapy.


Eligibility criteria:
inclusion criteria: * adult, prevalent hemodialysis patients * informed and consented * hemodialysis 3x/week via a tunneled cuffed catheter * urokinase administration at least two times during the previous 6 months (with more than a week between 2 administrations) * adequate catheter function during the week before inclusion (defined by blood flow more than 250ml/min on each dialysis session and blood flow within 15% of the maximal blood flow after the last urokinase administration) exclusion criteria: * presence of heparin-induced thrombocytopenia * major hemorrhage or intracranial bleeding in the previous 3 months * pericarditis * intolerance to taurolidine, citrate or to urokinase * active catheter-related infection * catheter in the femoral vein

Keywords: prevention, thrombosis, hemodialysis, vascular access device
effect of an advance care planning intervention

Conditions: Dementia

Summary: the intervention being studied is an advance care planning intervention. the trial has two arms: usual care and information arm.

eligible patients whose assisted living centers are randomized to the information arm will receive a letter from their clinician with links to informational video. eligible patients whose assisted living centers are randomized to the usual care arm have advance care planning discussions with a clinician at admission, annually, and sometimes with a hospitalization or other change in condition.

Eligibility criteria:
inclusion criteria: * partnering assisted living center with at least 20 patients with a dementia diagnosis (based on international classification of diseases, version 10 codes) * patients not on hospice * patients who do not have comfort care or do-not-hospitalize orders at baseline exclusion criteria: * partnering assisted living center with less than 20 patients with a dementia diagnosis (based on international classification of diseases, version 10 codes) * patients on hospice * patients with comfort care or do-not-hospitalize orders at baseline

Keywords: assisted living facilities dementia advance care planning
a study of peripheral blood progenitor cell (pbpc) mobilisation by chemotherapy with pegfilgrastim or filgrastim in subjects with non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of pbpcs for autologous transplantation after chemotherapy.


Eligibility criteria:
inclusion criteria: - subjects with non-hodgkin's lymphoma (nhl) who are considered to be suitable candidates for autologous pbpc transplantation per institution guidelines - ecog 0-2 inclusive - anc greater than 1.5 x 10\^9/l; plt greater than 100 x 10\^9/l exclusion criteria: - more than one line (regimen) of previous chemotherapy treatment and more than 2 cycles of any premobilisation salvage chemotherapy prior to enrolment. patients were also to be excluded from the study if they had received any salvage chemotherapy containing the following agents: procarbazine, nitrogen mustard, nitrosoureas (including bcnu), melphalan and fludarabine. - previous bone marrow or pbpc transplant - greater than 20% bone marrow involvement of the disease at time of screening, as demonstrated by biopsy - prior total nodal irradiation or any radiotherapy in the past 4 weeks - serum creatinine greater than 1.5 x upper limit of institutional normal range - total serum bilirubin greater than 2 x upper limit of institutional normal range - current diagnosis of splenomegaly not related to lymphoma - history of prior malignancy, except for lymphoma, curatively treated basal cell carcinoma, squamous cell carcinoma, in-situ cervical carcinoma or a surgically cured malignancy - any premalignant myeloid condition or any malignancy with myeloid characteristics (e.g., myelodysplastic syndromes, acute or chronic myelogenous leukaemia) - significant non-malignant disease, including documented hiv infection, uncontrolled hypertension (diastolic blood pressure greater than 115 mmhg), unstable angina, congestive heart failure (greater than ny heart association class ii), poorly controlled diabetes, coronary angioplasty within 6 months, uncontrolled atrial or ventricular cardiac arrhythmias, or active hepatitis c - haematopoietic growth factors administered within 1 week of study entry. if growth factor support was given during previous chemotherapy cycles, wbc less than 15.0 x 10\^9/l was required at enrolment - treatment with interferon® during the last 3 months - known hypersensitivity to e. coli-derived pharmaceutical products (e.g., filgrastim, humulin® insulin, l-asparaginase) - subject had previously been randomised into this study

Keywords: ice beam pbpc transplant
reliability and validity of the turkish version of the upper limb short questionnaire in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy; Upper Extremity Problem

Summary: purpose: this study aimed to evaluate the construct validity and reliability of the turkish version of the upper limb short questionnaire (ulsq) in duchenne muscular dystrophy (dmd). materials and methods: a total of 41 children with dmd have participated in the study. upper and lower extremities functional levels were assessed with vignos scale and brooke upper extremity functional rating scale, respectively. the construct validity of the questionnaire was determined using the correlation between the ulsq and abilhand-kids. the cronbach alpha value was calculated to determine internal consistency. to determine test-retest reliability, 17 randomly selected children were evaluated seven days after the first evaluation, and the "intraclass correlation coefficient (icc)" value was calculated.


Eligibility criteria:
inclusion criteria: * being diagnosed with dmd, being between the ages of 5-18, not having any additional neurological disorder, volunteering to participate in the research exclusion criteria: * patients diagnosed after 10 years of age, patients who had never taken corticosteroids, and patients aged 14 years or older but were still ambulatory
artificial intelligence in functional imaging for individualized treatment of head and neck squamous cell carcinoma patients

Conditions: HNSCC

Summary: the two curative treatment modalities for patients with hnscc - primary chemoradiation (crt) or primary surgery (often combined with postoperative (c)rt) - are both associated with serious side effects for which reason further stratification, optimization and personalization of treatment is urgently needed. as novel quantitative image analyses are a promising tool for further risk stratification, the investigators training a three-dimensional convolutional neural network on 18f-fluorodesoxyglucose (fdg) positron emission tomography (pet) imaging and clinical / histopathological data of a multicentric, retrospective cohort of 1200 patients treated with primary crt and 800 patients treated with primary surgery at charité and cooperation institutes in order to predict individual treatment-specific outcomes and identify patients with excellent outcome after primary crt or primary surgery or unfavorable outcome for both. the trained algorithm of the artificial intelligence will be validated in a prospective trial to see if predicted loco-regional control and recommended treatment strategies are reliable. in total 250 curative hnscc patients, treated with crt or primary surgery, will be enrolled on this prospective validation trial with observational character, while biomarker, clinical and fdg-pet data are collected from these patients and follow-up visits will be concluded.


Eligibility criteria:
inclusion criteria: * all patients older than 18 years with diagnosed hnscc, attending the department of radiooncology and radiotherapy or the department of oral and maxillofacial surgery at charité for a treatment with curative intension ( r(c)t or primary surgery / combined). * all patients received as pretherapeutic diagnostic method a 18f-fluorodesoxyglucose (fdg) positron emission tomography (pet) imaging exclusion criteria: * patients with hnscc who cannot be treated in a curative approach * patients with hnscc treated in a curative approach but unable to receive fdg pet imaging before start of treatment * data from patients who have withdrawn their study consent
delayed postconditioning

Conditions: Myocardial Reperfusion Injury

Summary: the investigators previously reported that angioplasty postconditioning reduces infarct size (cardiac enzyme release) in stemi patients with a fully occluded coronary artery at hospital admission. animal studies have suggested that the time window for applying brief episodes of ischemia and reperfusion aimed at triggering postconditioning's protection is very narrow, i.e. does not expand beyond 1 minute after reflow. we sought to address whether this window might be larger in humans, i.e. whether stemi patients might be protected several minutes after undergoing spontaneous reperfusion before admission coronary angiography. therefore, stemi patients (onset of chest pain less than 12 hours) with a timi flow grade \> 1 were eligible for that study. angioplasty postconditioning was completed as already published and infarct size was assessed by measuring cardiac enzymes release.


Eligibility criteria:
inclusion criteria: * patient \> 18 years old * male or female * presenting first myocardial infarction, with the beginning of pains \< 12 hours, * requiring a revascularisation by primary angioplasty or " rescue " (after failure of thrombolysis) on lad or rca (not circumflex coronary artery). * timi flow grade at admission of 2 or 3 * lv angiography (rao30°) before angioplasty. exclusion criteria: * cardiac arrest before the angioplasty * cardiogenic shock * occlusion of the artery circumflex responsible for the infarction * visible collaterals to the area at risk * magnetic resonance imaging: contra indication

Keywords: myocardial infarction postconditioning
modulation of intestinal and pulmonary inflammation by lactobacillus diet supplementation in pediatric cystic fibrosis

Conditions: Pulmonary Inflammation; Cystic Fibrosis; Microbiota

Summary: pulmonary inflammation is an independent risk factor for disease progression in cystic fibrosis patients (cf). yet, no effective treatment is known to reduce this detrimental inflammation. dysbiosis of the gut microbiota has been linked to inflammation in several inflammatory diseases. as children with cf have different faecal microbiota from their healthy siblings, modulating gut microbiota by lactobacillus rhamnosus diet supplementation might be a strategy to target the inflammatory state in cf. study subjects (cf or healthy control) will receive either placebo or lactobacillus rhamnosus once daily as dietary supplementation for 12 weeks. after a one-week washout phase, they will be switched for another 12 weeks to the other trial arm. effect on in intestinal and pulmonary inflammation as well as clinical outcome will be studied.


Eligibility criteria:
inclusion criteria: * moderate to severe cf disease exclusion criteria: * acute gastroenteritis 2 weeks prior to inclusion * chronic disease other than cf (except cf associated disorders) * oral or parenteral antibiotics 2 weeks prior to inclusion * systemic steroids 4 weeks prior to inclusion * any probiotic intake
prevention of adhesions following flexor tendon injury within zone ii with vascularized finger dorsal fascial flap

Conditions: Tendon Injuries

Summary: the purpose of this study was to report a new method of flexor tendon repair in zone ii with combined standard modified kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger volar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons. the function outcomes of 14 patients (group a) with flexor tendon repair in zone ii with this new technique were compared with those of 32 patients (group b) with flexor tendon repair in zone ii with standard modified kessler technique. this new technique may prevent serious adhesions between flexor digitorum superficialis /profundus tendons.


Eligibility criteria:
inclusion criteria: * patients requiring flexor tendon repair or reconstruction within zoneⅱ exclusion criteria:

Keywords: tendon repair
study of retinal and choriocapillary vascular changes in patients undergoing tadalafil 20mg

Conditions: Erectile Dysfunction Following Radical Prostatectomy

Summary: this study evaluates the retinal and choriocapillary vascular features in patients under the effects of tadalafil 20mg using optical coherence tomography angiography.

tadalafil is a an inhibitor of the enzyme phosphodiesterase and it works by increasing blood flow to the penis thus promoting the erection. this drug represents an treatment for erectile dysfunction in patients after radical prostatectomy. the optical coherence tomography angiography represents a novel and non-invasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features. the study evaluates the changes in optical coherence tomography angiography parameters at baseline and after 1, 3, 6 months after the somministration of tadalafil 20 mg orally.

Eligibility criteria:
inclusion criteria: * age older than 45 years * diagnosis of erectile dysfunction due to surgery of radical prostatectomy * treatment-naïve with tadalafil for erectile dysfunction * absence of vitreoretinal and vascular retinal diseases * absence of diabetes exclusion criteria: * age younger than 45 years * diagnosis of erectile dysfunction due to other causes * previous treatments before tadalafil for erectile dysfunction * presence of vitreoretinal and vascular retinal diseases * presence of diabetes.